Gradientech appoints Veronica Byfield Sköld to Board of Directors
The diagnostics company Gradientech today announces the appointment of Veronica Byfield Sköld to its Board of Directors, effective May 21, 2025. Following her appointment, the Board now comprises six directors.
Veronica Byfield Sköld brings over 25 years of experience in international medtech and life sciences. She has held senior commercial roles at companies including Elekta and Permobil, and served as CEO of the biotech company BioLamina until 2024. Her previous experience also includes positions at Boston Consulting Group (BCG), Gambro, and as Partner at the private equity firm Impilo, where she currently remains on the Board. In addition, she serves on the Board of Dansens Hus, and holds an MSc in Industrial Engineering and Management from KTH Royal Institute of Technology.
“I’m truly excited about the opportunity to join Gradientech’s Board at this pivotal stage in the company’s development. The company’s innovative technology addresses a critical and growing need in the clinical diagnostics market, with the potential to significantly improve the diagnosis and treatment of sepsis—ultimately leading to better clinical outcomes. I’m deeply motivated to contribute to this important journey in any way I can,” says Veronica Byfield Sköld.
“We are pleased to welcome Veronica Byfield Sköld to the Gradientech Board,” says Gisela Sitbon, Chairman of the Board. “She brings extensive experience in international medtech and life sciences, combined with a strong track record in strategic and commercial leadership, as we now continue our growth journey. I would also like to thank Laura Chirica for her dedicated work during her years in the Gradientech Board.”
The appointment follows the departure of Dr. Laura Chirica, who did not stand for re-election at the Gradientech Annual General Meeting. Dr. Chirica had served on the Board since 2021.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, contributes to the effective management of sepsis patients by supporting antibiotic treatment decisions in record time. This helps save lives, reduce healthcare costs, and combat the spread of antibiotic resistance – one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit www.gradientech.se for more information.